Neoadjuvant and Adjuvant Therapy — MCQs
Most favorable prognosis after radiotherapy is in -
Compared to the other options, radiotherapy is LEAST commonly used as a primary treatment modality in:
Which of the following cancers are correctly matched with the criteria for the minimum number of lymph nodes required for pathological staging? A. CA stomach -10 B. CA colon -12 C. CA gall bladder -6 D. CA breast -15
What is the primary treatment for early-stage non-small cell lung cancer?
What is the most appropriate next step in management for a patient with a Stage III ovarian cancer with partial response to platinum-based chemotherapy?
Treatment of resectable T4N0M0 stage of head and neck carcinoma is?
What is the treatment of choice for a patient presenting with carcinoma of the rectum and obstruction in an emergency setting?
In a 65 year old, double contrast barium enema shows cancer of colon with an apple core appearance. Colonoscopic biopsy shows adenocarcinoma. What will be the next step of management?
Which of the following is the best indicator of prognosis of soft tissue sarcoma?
Which of the following is not done in carcinoma esophagus?
Neoadjuvant and Adjuvant Therapy Indian Medical PG Practice Questions and MCQs
Question 1: Most favorable prognosis after radiotherapy is in -
- A. Teratoma
- B. Desmoid
- C. Seminoma (Correct Answer)
- D. Melanoma
Explanation: ***Seminoma*** - **Seminoma** is highly **radiosensitive**, meaning it responds very well to radiation therapy, leading to excellent oncological outcomes. - Due to its sensitivity, even advanced seminomas can often be cured with radiotherapy, contributing to a **favorable prognosis**. *Teratoma* - **Teratomas** are generally **radioresistant**, meaning they do not respond well to radiation therapy. - Treatment for teratomas typically involves **surgical resection**, as radiation is largely ineffective. *Desmoid* - **Desmoid tumors** (aggressive fibromatosis) are locally aggressive but rarely metastasize, and their response to radiotherapy is variable. - While radiation can be used for local control, the prognosis is often complicated by **local recurrence** and challenging surgical margins. *Melanoma* - **Melanoma** is notoriously **radioresistant**, making radiation therapy a less effective primary treatment option. - It is often used for **palliative care** or in cases of local recurrence, but rarely leads to a cure or favorable prognosis when used alone.
Question 2: Compared to the other options, radiotherapy is LEAST commonly used as a primary treatment modality in:
- A. Esophageal cancer
- B. Brain tumor
- C. Cervical cancer
- D. Stomach cancer (Correct Answer)
Explanation: ***Stomach cancer*** - **Radiotherapy** is generally *not* a primary treatment for **stomach cancer** due to the high radiosensitivity of surrounding organs (e.g., small bowel, liver, kidneys) and the difficulty in delivering a curative dose without significant toxicity. - While it may be used as an **adjuvant therapy** post-surgery or for **palliative care** (e.g., pain, bleeding), it is rarely the initial standalone treatment. *Esophageal cancer* - **Radiotherapy** is a common primary or neoadjuvant treatment for **esophageal cancer**, often in combination with chemotherapy (**chemoradiation**), especially for unresectable cases or to downstage tumors before surgery. - It plays a significant role in both curative intent and **palliative management** for dysphagia. *Brain tumor* - **Radiotherapy** is a cornerstone of treatment for many primary and metastatic **brain tumors**, often following surgical resection or as a standalone primary treatment. - Techniques like **stereotactic radiosurgery (SRS)** and **intensity-modulated radiation therapy (IMRT)** allow for precise targeting, minimizing damage to healthy brain tissue. *Cervical cancer* - **Radiotherapy**, particularly external beam radiation therapy (EBRT) combined with **brachytherapy**, is a highly effective primary treatment for **locally advanced cervical cancer**, especially if surgery is not feasible or desired [1]. - It can achieve high cure rates and is often given concurrently with chemotherapy (**chemoradiation**) [1].
Question 3: Which of the following cancers are correctly matched with the criteria for the minimum number of lymph nodes required for pathological staging? A. CA stomach -10 B. CA colon -12 C. CA gall bladder -6 D. CA breast -15
- A. A,B,C
- B. A,B,C,D
- C. B,C (Correct Answer)
- D. A,C,D
Explanation: ***B,C (Correct Answer)*** - **Colorectal cancer (B)** requires a minimum of **12 lymph nodes** for adequate pathological staging - **correctly matched** ✅ - **Gallbladder cancer (C)** requires at least **6 lymph nodes** for proper staging - **correctly matched** ✅ - These are the only two correctly matched pairs in the question - Adequate lymph node retrieval is essential to prevent **understaging** and ensure accurate prognostic assessment *A,B,C (Incorrect)* - While B and C are correct, **gastric cancer (A)** requires a minimum of **15 lymph nodes**, not 10 - The inclusion of A makes this combination incorrect *A,B,C,D (Incorrect)* - **Gastric cancer (A)** requires **15 lymph nodes**, not 10 - **incorrectly matched** - **Breast cancer (D)** requires a minimum of **10 lymph nodes**, not 15 - **incorrectly matched** - Only B and C are correctly matched *A,C,D (Incorrect)* - **Gastric cancer (A)** requires **15 lymph nodes**, not 10 - **incorrectly matched** - **Breast cancer (D)** requires **10 lymph nodes**, not 15 - **incorrectly matched** - C is correct, but A and D are both incorrectly matched
Question 4: What is the primary treatment for early-stage non-small cell lung cancer?
- A. Radiotherapy
- B. Surgical resection (Correct Answer)
- C. Surgical resection with adjuvant chemotherapy
- D. Immunotherapy
Explanation: ***Surgical resection*** - **Surgical resection** (lobectomy or segmentectomy with lymph node dissection) is the **primary and definitive treatment** for early-stage non-small cell lung cancer (Stage I-II). - For **Stage IA disease**, surgery alone provides excellent outcomes with 5-year survival rates of 70-90%, and adjuvant chemotherapy is generally **not indicated**. - For **Stage IB-II**, surgery remains primary, with adjuvant chemotherapy considered selectively based on tumor size (>4 cm), poor differentiation, vascular invasion, or other high-risk features. - Complete surgical resection offers the **best chance of cure** for resectable early-stage NSCLC. *Surgical resection with adjuvant chemotherapy* - While this combination is important for **select early-stage cases** (high-risk Stage IB, Stage II-IIIA), it is **not the universal primary treatment** for all early-stage disease. - Adjuvant chemotherapy is an **addition** to surgery in specific scenarios, not part of the primary treatment for the majority of early-stage (especially Stage IA) patients. - Current guidelines recommend risk stratification before adding adjuvant therapy. *Radiotherapy* - **Radiotherapy** (stereotactic body radiotherapy/SBRT) is reserved for **medically inoperable** patients or those who refuse surgery. - It is not the primary treatment when the patient is a **surgical candidate**. - May be used as adjuvant therapy in patients with positive margins or N2 disease. *Immunotherapy* - **Immunotherapy** has emerging roles in neoadjuvant/adjuvant settings for resectable NSCLC (recent trials showing benefit). - However, it is **not established as primary monotherapy** for early resectable disease. - More commonly used in advanced/metastatic NSCLC or as part of combination regimens in clinical trial settings for early disease.
Question 5: What is the most appropriate next step in management for a patient with a Stage III ovarian cancer with partial response to platinum-based chemotherapy?
- A. Bevacizumab
- B. Perform surgery (Correct Answer)
- C. Switch to radiotherapy
- D. Continue regimen
Explanation: ***Perform surgery (Interval Debulking Surgery)*** - In **Stage III ovarian cancer**, after an initial partial response to **platinum-based chemotherapy**, **interval debulking surgery** is the standard next step to remove residual disease. - This approach aims to reduce tumor burden to an optimal level (< 1 cm residual disease), which has been shown to improve overall survival in multiple trials (EORTC 55971, GOG-152). - Performed after 3-4 cycles of neoadjuvant chemotherapy when the patient has demonstrated response and is medically fit for surgery. *Bevacizumab* - **Bevacizumab** is an **anti-angiogenic agent** used in ovarian cancer, typically as part of frontline maintenance therapy or for recurrent disease, not as the immediate next step after partial response to primary chemotherapy when surgery is feasible. - While it can be incorporated into maintenance treatment post-surgery, it's not the primary next step after partial response when interval debulking surgery is indicated. *Switch to radiotherapy* - **Radiotherapy** has a limited role in the primary treatment of advanced ovarian cancer due to its widespread peritoneal nature. - It is sometimes used for localized recurrence or symptom palliation, but not as a standard next step after partial response to chemotherapy in Stage III disease. *Continue regimen* - Continuing the same regimen after only a **partial response** is generally not the most effective strategy when further tumor reduction via surgery is possible. - The goal in advanced ovarian cancer is **maximal cytoreduction**, and if residual disease is present after neoadjuvant chemotherapy, interval debulking surgery is preferred over continued chemotherapy alone.
Question 6: Treatment of resectable T4N0M0 stage of head and neck carcinoma is?
- A. Radiotherapy alone
- B. Surgery and Radiotherapy (Correct Answer)
- C. Chemoradiation
- D. Surgery alone
Explanation: ***Surgery and Radiotherapy*** - For **resectable T4N0M0 head and neck carcinoma**, the standard treatment is **surgical resection** of the primary tumor followed by **adjuvant radiotherapy**. - This approach achieves optimal **local control** for advanced primary tumors without nodal involvement. - **Adjuvant radiotherapy** is essential for T4 tumors due to high risk of microscopic residual disease and local recurrence. - Surgery allows for complete tumor removal with negative margins, while radiotherapy addresses subclinical disease. *Radiotherapy alone* - Radiotherapy alone is **insufficient as monotherapy** for T4 tumors due to the large tumor burden and extensive local invasion. - Single modality radiation cannot reliably achieve adequate tumor control for advanced primary lesions. - Generally reserved for early-stage disease or patients unfit for surgery. *Chemoradiation* - **Definitive chemoradiation** is an alternative for **unresectable T4 tumors** or when organ preservation is desired (e.g., laryngeal cancer). - For **resectable** T4N0M0 disease, surgery with adjuvant RT is preferred as it provides better local control and allows pathological staging. - Chemoradiation may be used postoperatively if high-risk features are found (positive margins, perineural invasion, extranodal extension). - In this **N0 case with resectable tumor**, upfront surgery is the preferred initial approach. *Surgery alone* - While surgical resection is crucial for T4 tumors, **surgery alone is inadequate** due to high risk of locoregional recurrence. - T4 classification indicates extensive local invasion, necessitating **adjuvant radiotherapy** to eradicate microscopic disease. - Combined modality treatment (surgery + RT) significantly improves local control and survival compared to surgery alone.
Question 7: What is the treatment of choice for a patient presenting with carcinoma of the rectum and obstruction in an emergency setting?
- A. Total colectomy
- B. Hartmann's procedure (Correct Answer)
- C. Defunctioning colostomy
- D. Left hemi-colectomy
Explanation: ***Hartmann's procedure*** - In an emergency setting with **obstructing carcinoma of the rectum**, Hartmann's procedure is the **treatment of choice**. - This procedure involves **resection of the tumor** with formation of an **end colostomy** and closure of the distal rectal stump. - It achieves **dual objectives**: relieves the obstruction AND removes the primary tumor, allowing proper oncological staging and planning of adjuvant therapy. - While more extensive than simple diversion, it is the **standard emergency operation** for obstructing left-sided and rectal cancers in patients who can tolerate resection. - The colostomy can be reversed later after adjuvant treatment (if needed), though many remain permanent. *Defunctioning colostomy* - A proximal diverting colostomy only diverts the fecal stream without addressing the primary tumor. - This is a **temporizing measure**, not definitive treatment, and leaves the malignancy in situ. - It may be considered in **highly unstable patients** or for purely **palliative** intent when resection is not feasible. - Requires a second major operation for definitive tumor resection, increasing overall morbidity. *Total colectomy* - This involves removing the entire colon and is performed for conditions like **familial adenomatous polyposis** or **synchronous colon cancers**. - Not indicated for isolated rectal cancer with obstruction. - Would be excessively extensive and carry unnecessary morbidity in this setting. *Left hemi-colectomy* - This procedure removes the left colon (descending and sigmoid) but typically does not include the rectum. - Not appropriate for **rectal cancer**, as it would not address the primary pathology. - Used for tumors of the descending or sigmoid colon, not rectum.
Question 8: In a 65 year old, double contrast barium enema shows cancer of colon with an apple core appearance. Colonoscopic biopsy shows adenocarcinoma. What will be the next step of management?
- A. Surgery
- B. Radiotherapy
- C. Chemotherapy
- D. CECT to stage disease (Correct Answer)
Explanation: ***CECT to stage disease*** - **CECT (Contrast-Enhanced CT) of chest, abdomen, and pelvis is the essential next step** after histological confirmation of colon adenocarcinoma. - **Staging is mandatory** before any treatment decision to determine: - **Local extent** of tumor (T stage) - **Lymph node involvement** (N stage) - **Distant metastases** (M stage - liver, lungs, peritoneum) - **Resectability** and surgical planning - Even with the "apple core" appearance indicating an advanced primary tumor, **treatment decisions cannot be made without knowing the overall disease burden**. - **CEA (Carcinoembryonic Antigen) levels** are also typically obtained during staging. *Surgery* - **Surgical resection is the definitive treatment** for localized, resectable colon cancer and would be performed **after staging**, not before. - Surgery involves removing the tumor with adequate margins and regional lymphadenectomy. - However, **staging must precede surgery** to: - Determine if the disease is metastatic (which would change surgical approach) - Plan the extent of resection - Counsel the patient appropriately - Decide on neoadjuvant therapy if indicated - The "apple core" appearance suggests an advanced primary but does not indicate acute obstruction requiring emergency surgery in this stable patient who has already undergone barium enema and colonoscopy. *Chemotherapy* - **Chemotherapy** is typically given as: - **Adjuvant therapy** after surgery for stage III (node-positive) or high-risk stage II disease - **Palliative therapy** for metastatic (stage IV) disease - **Neoadjuvant therapy** is not standard for colon cancer (unlike rectal cancer) - Chemotherapy is not the immediate next step; staging and then surgery (if resectable) come first. *Radiotherapy* - **Radiotherapy has limited role in colon cancer** (unlike rectal cancer where it is commonly used). - It may be used for: - **Palliation** of symptoms (pain, bleeding) in advanced disease - Rare cases of **locally advanced unresectable disease** - It is not a primary treatment modality and is not the next step in this case.
Question 9: Which of the following is the best indicator of prognosis of soft tissue sarcoma?
- A. Tumour size
- B. Nodal metastasis
- C. Histological type
- D. Tumour grade (Correct Answer)
Explanation: ***Tumour grade*** - **Tumor grade** quantifies the degree of cellular differentiation, mitotic activity, and necrosis within the tumor, reflecting its aggressive potential. - A **higher tumor grade** is directly associated with a poorer prognosis, increased risk of local recurrence, and distant metastasis in soft tissue sarcomas. *Tumour size* - While larger tumor size (e.g., >5 cm) is generally associated with a worse prognosis, it is primarily a factor in **staging**, not the most critical prognostic indicator. - **Tumor grade** provides more fundamental information about the biological aggressiveness of the tumor cells regardless of their current size. *Nodal metastasis* - **Nodal metastasis** in soft tissue sarcomas is relatively uncommon (less than 5% of cases) compared to carcinomas, and its presence is a significant negative prognostic factor. - However, because it is rare, it doesn't serve as the *primary* indicator for the majority of sarcoma patients, where tumor grade is more universally applicable. *Histological type* - The **histological type** (e.g., liposarcoma, leiomyosarcoma) helps classify the sarcoma, but different subtypes can have a wide range of biological behavior. - While certain types may have a generally better or worse prognosis, the **grade** *within* that histological type is a more precise predictor of individual patient outcomes.
Question 10: Which of the following is not done in carcinoma esophagus?
- A. pH - metry/monitoring (Correct Answer)
- B. CT chest
- C. PET scan
- D. Biopsy
Explanation: ***pH - metry/monitoring*** - **pH metry/monitoring** is primarily used to diagnose **gastroesophageal reflux disease (GERD)**, which is not a direct diagnostic tool for esophageal carcinoma itself. - While GERD is a risk factor for **Barrett's esophagus** and subsequently adenocarcinoma of the esophagus, pH monitoring does not directly identify or stage the cancer. *CT chest* - **CT (Computed Tomography) chest** is routinely performed in esophageal carcinoma to assess the **local extent** of the tumor and identify potential **lymph node involvement** or **metastasis** to other organs. - It is crucial for **staging** the disease and guiding treatment decisions such as resectability. *PET scan* - A **PET (Positron Emission Tomography) scan** is highly useful for detecting **distant metastases** and identifying **occult disease** not visible on CT, especially in cases of suspected advanced esophageal carcinoma. - It helps in **accurate staging** and avoiding futile surgery in patients with metastatic disease. *Biopsy* - **Biopsy**, typically performed during endoscopy, is the **gold standard** for confirming the diagnosis of esophageal carcinoma by obtaining tissue for **histopathological examination**. - It identifies the cell type (e.g., adenocarcinoma, squamous cell carcinoma) and grade of the tumor, which is essential for treatment planning.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free